Biotechnology
AGC Biologics Completes PPQ Manufacturing Campaign with Provention Bio for Type 1 Diabetes Product Candidate, Teplizumab
SEATTLE, Aug. 25, 2020 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), achieved the on-schedule completion of a drug substance Process Performance Qualification (PPQ) campaign, focused on teplizumab (PRV-031) for partn...
2020-08-25 22:00
5767
FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations
- Tepotinib granted Priority Review and is being evaluated under FDA Real-Time Oncology Review (RTOR) pilot program - Tepotinib is a highly targeted inhibitor of c-MET that is administered as a once-daily oral tablet - Data show robust, consistent and durable clinical response across different ...
2020-08-25 21:22
2687
Global Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2021
HONG KONG, Aug. 25, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for...
2020-08-25 04:16
18842
One Drop Announces Nearly $100M Financing And Commitments By Bayer
$98.7M financing, development fees and commercial milestone commitments accelerate the development and commercialization of One Drop's digital health platform and data-driven predictive capabilities across multiple therapeutic areas NEW YORK, Aug. 24, 2020 /PRNewswire/ -- One Drop, a leader in d...
2020-08-24 19:00
4384
Singapore's Restalyst develops highly sensitive COVID-19 antibody test comparable to market leaders
SINGAPORE, Aug. 24, 2020 /PRNewswire/ -- Singapore biomedical firm Restalyst has developed a COVID-19 antibody test, COVID19N-REAAD™, which will be instrumental in establishing disease prevalence in populations and the exposure risk factors associated with infection. This will enable healthcare a...
2020-08-24 12:42
2571
US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG
SYDNEY, Aug. 24, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxalisib (formerl...
2020-08-24 09:14
6602
Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to treat Critical Limb Ischemia (CLI)
MUMBAI, India, Aug. 21, 2020 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General ofIndia (DCGI) for the launch of Stempeucel® in India. The...
2020-08-21 06:00
9668
Ascletis Completed Bridging Study of ASC18, a One-pill, Once-a-day Complete HCV Oral Regimen
HANGZHOU and SHAOXING, China, Aug. 20, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today that it completed bridging study of ASC18, first one-pill, once-a-day fixed dose combination (FDC) as the complete hepatitis C treatment developed by a Chinese biotech. ASC18 FDC co...
2020-08-20 20:00
4147
Low-Cost Nafamostat Blocks SARS-CoV-2 Infection in Human Lung Cells, Preclinical Study Finds
SAN DIEGO, Aug. 20, 2020 /PRNewswire/ -- A preclinical study testing the low-cost generic drug nafamostat in human cells shows it can help block SARS-CoV-2 infection, raising excitement around Covistat's work to develop prophylactic and therapeutic COVID-19 treatments. Biopharmaceutical company ...
2020-08-20 19:00
2813
Visiopharm granted patents for stain quality management in Tissue Biomarkers
HOERSHOLM, Denmark, Aug. 20, 2020 /PRNewswire/ -- Visiopharm®, the Denmark -based leader in artificial intelligence-driven image analysis, tissue mining, and precision pathology, has been granted patents in the US andEurope for an AI and image analysis-based approach to quantifying staining qualit...
2020-08-20 14:00
2496
Zymo Research Granted CE IVD Mark for Quick SARS-CoV-2 rRT-PCR Kit
IRVINE, California, Aug. 20, 2020 /PRNewswire/ -- Zymo Research announced that it was recently granted the CE IVD Mark for itsQuick SARS-CoV-2 rRT-PCR Kit. To obtain this certification the product had to comply with the Directive 98/79/EC of the European Parliament and of the Council of27 October...
2020-08-20 09:35
3895
US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma
SYDNEY, Aug. 20, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kazia's paxalisib (forme...
2020-08-20 08:35
8721
Harbour BioMed, Utrecht University, Erasmus Medical Center, Viroclinics-DDL and Kiadis Pharma Announce Collaboration to Develop Monoclonal Antibody, Natural Killer Cell Combination Approach to Treating COVID-19
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Aug. 19, 2020 /PRNewswire/ -- Harbour BioMed (HBM), and its partnersUtrecht University and Erasmus Medical Center, today announced a new research collaboration with Viroclinics-DDL and Kiadis Pharma (Euronext Amsterdam and Brussels: K...
2020-08-19 19:43
3233
Global Entertainment Giant YOOZOO Aligns with Health Tech Company Plano to Tackle the Global Myopia Epidemic
SINGAPORE, Aug. 19, 2020 /PRNewswire/ -- Plano Pte Ltd (hereinafter, Plano), a Singapore-based health technology startup, and one of the world's leading providers of interactive entertainment, YOOZOO, have inked a Memorandum of Understanding to address the global burden of myopia inSingapore, the...
2020-08-19 12:00
4614
CStone Pharmaceuticals Reports Financial Results for the First Half of 2020
SUZHOU, China, Aug. 19, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology (IO) therapies and precision medicines, today reported recent business highlights and financial resu...
2020-08-19 09:33
4640
Ascentage Pharma Releases 2020 Interim Results, Reporting the Company's First New Drug Application and Advances in Global Strategic Collaborations
SUZHOU, China and ROCKVILLE, Md., Aug. 18, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its interim results for the ...
2020-08-18 20:24
3868
Global Cord Blood Corporation to Report First Quarter Fiscal 2021 Financial Results
HONG KONG, Aug. 18, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release financial results fo...
2020-08-18 19:00
11518
WuXi Biologics Records Excellent Interim Results
Revenue Up 21.0% Y-o-Y to RMB1,944.1 Million Net Profit Up 62.6% to RMB730.7 Million Profit Attributable to Owners of the Company Up 63.6% Y-o-Y to RMB736.1 Million Adjusted Net Profit Up 40.7% Y-o-Y to RMB734.0 Million Diluted EPS Up 55.9% Y-o-Y to RMB0.53 Adjusted Diluted EPS Up 38.5% Y-o-Y to RMB...
2020-08-18 00:51
3336
Sirtex Medical announces partnership with Magle Chemoswed
Collaboration grants Sirtex global use of innovative technology to develop novel imaging agent for interventional oncology WOBURN, Massachusetts, Aug. 17, 2020 /PRNewswire/ -- Sirtex Medical US Holdings, Inc. ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced a coll...
2020-08-17 20:00
2371
First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody
HANGZHOU, China and SHAOXING, China, Aug. 17, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today dosing of the first HBV patient in Phase IIa clinical trial of ASC22, which is a first-in-class, subcutaneously administered PD-L1 antibody. ASC22(Envafolimab) Phase IIa clin...
2020-08-17 08:30
4010
Week's Top Stories
Most Reposted
UTP LAUNCHES MALAYSIA'S FIRST BACHELOR IN INTEGRATED ENGINEERING PROGRAMME
[Picked up by 305 media titles]
2024-12-27 13:17
XTransfer and OCBC Jointly Announce Comprehensive Partnership
[Picked up by 266 media titles]
2024-12-23 17:36
CKGSB Successfully Hosts 2024 MBA Professor Training Program for Western China
[Picked up by 253 media titles]
2024-12-24 00:06ebm-papst A&NZ Achieves Complete Operational Carbon Neutrality in appropriate Scope 1,2 and 3 criterion in 2023
[Picked up by 246 media titles]
2024-12-25 15:45Huawei Cloud Named a Challenger in Gartner® Magic Quadrant™ for Cloud DBMSs
[Picked up by 239 media titles]
2024-12-27 11:24
Most Read
/C O R R E C T I O N -- Ellington Properties/
2024-12-27 20:57
7420
XTransfer and OCBC Jointly Announce Comprehensive Partnership
2024-12-23 17:36
5814
CKGSB Successfully Hosts 2024 MBA Professor Training Program for Western China
2024-12-24 00:06
5018
Zoomlion Releases the World's Tallest Straight Boom Aerial Work Platform
2024-12-24 17:56
4829
